Dual Blockade of Inhibitory Immunoreceptors TIGIT and PD-1 Produces Optimal Synergistic Anti-Tumor Effects

Autores/as

  • Paige Kramer

DOI:

https://doi.org/10.17161/mjusc.v1i1.18573

Palabras clave:

Immunology, TIGIT, PD-1, checkpoint inhibitors, tumor, cancer

Resumen

Recent investigation into immunoregulatory roles of both TIGIT and PD-1 T cell receptors reveals that their suppressive effects converge with the inhibition of another T cell receptor, CD226. Co-blockade of these receptors reduced tumor volume in vivo and shows potential as a promising new cancer immunotherapy.

Cover of issue 1 of the Midwestern Journal of Undergraduate Sciences showing an illustration of checkpoint inhibitors

Descargas

Publicado

2022-10-03

Número

Vol. 1 Núm. 1 (2022)

Sección

Reviews

Licencia

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.

© The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license. 

Cómo citar

Kramer, P. (2022). Dual Blockade of Inhibitory Immunoreceptors TIGIT and PD-1 Produces Optimal Synergistic Anti-Tumor Effects. Midwestern Journal of Undergraduate Sciences, 1(1), 3-4. https://doi.org/10.17161/mjusc.v1i1.18573